Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET) - Rosenstock, Julio; Frias, Juan; Páll, Dénes; Charbonnel, Bernard; Pascu, Raluca; Saur, Didier; Darekar, Amanda; Huyck, Susan; Shi, Harry; Lauring, Brett; Terra, Steven G. (Diabetes, obesity & metabolism, 2018)
Keywords: Adult; Aged; Antidiabetics; Blood Glucose - drug effects; Blood Glucose - metabolism; Blood pressure; Blood Pressure - drug effects; Body weight; Bone density; Bone Density - drug effects; Bone mineral density; Bridged Bicyclo Compounds, Heterocyclic - administration & dosage; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - physiopathology; Diabetes Mellitus, Type 2 - prevention & control; Double-Blind Method; ertugliflozin; Female; Glycated Hemoglobin A - metabolism; Humans; Hypoglycemia; Hypoglycemic Agents - administration & dosage; Infections; Male; Metformin; Metformin - administration & dosage; Middle Aged; SGLT2 inhibitor; Sodium-Glucose Transporter 2 Inhibitors - administration & dosage; Treatment Outcome; type 2 diabetes mellitus; Urinary tract; Weight Loss - drug effects; Young Adult; type 2 diabetes mellitus; bone mineral density; ertugliflozin; SGLT2 inhibitor